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Abstract 
Elongin A is the transcriptionally active subunit of the Elongin complex that strongly 
stimulates the rate of elongation by RNA polymerase II (pol II) by suppressing the 
transient pausing of the polymerase at many sites along the DNA template. We have 
recently shown that Elongin A-deficient mice are embryonic lethal, and mouse 
embryonic fibroblasts (MEFs) derived from Elongin A-/- embryos display not only 
increased apoptosis but also senescence-like phenotypes accompanied by the activation 
of p53. To further understand the function of Elongin A in vivo, we have carried out the 
structure-function analysis of Elongin A and identified sequences critical to its nuclear 
localization and direct interaction with pol II. Moreover, we have analyzed the 
replication fork movement in wild-type and Elongin A-/- MEFs, and shown the 
possibility that the genomic instability observed in Elongin A-/- MEFs might be caused 
by the replication fork collapse due to Elongin A deficiency. 
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Eukaryotic messenger RNA synthesis by RNA polymerase II (pol II) is regulated by 
the concerted action of a set of general transcription factors that control the activity of 
pol II during the initiation and elongation stages of transcription. At least six general 
transcription initiation factors (TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH) have 
been identified in eukaryotic cells and found to promote the selective binding of pol II 
to promoters and to support a basal level of transcription [1]. In addition, a diverse 
collection of elongation factors that promote the efficient elongation of transcripts by 
pol II on naked DNA templates in vitro have been identified biochemically [2-4]. These 
elongation factors fall into two broad functional classes based on their ability to either 
reactivate arrested pol II or suppress the transient pausing of pol II. The first class is 
composed of members of the SII family [2, 5]. The second class is comprised of a 
collection of elongation factors, including TFIIF [6], Elongin [7, 8], ELL [9] and 
Cockayne syndrome B (CSB) protein [10], which increase the overall rate of mRNA 
chain elongation by decreasing the frequency and/or duration of the transient pausing of 
pol II at sites along the DNA template. 
Elongin was initially identified as a heterotrimeric protein composed of A, B and C 
subunits of ~770, 118 and 112 amino acids, respectively [7, 8, 11, 12]. Elongin A is the 
transcriptionally active subunit, whereas Elongins B and C are positive regulatory 
subunits that can form an isolable Elongin BC subcomplex [8, 13, 14]. Recently, we 
have generated Elongin A-deficient mice by gene targeting [15]. Elongin A-/- embryos 
exhibited severely retarded growth and died at between days 10.5 and 12.5 of gestation, 
most likely due to excessive apoptosis. Moreover, mouse embryonic fibroblasts (MEFs) 
derived from Elongin A-/- embryos displayed not only increased apoptosis but also 
senescence-like growth defects accompanied by the activation of p53. 
As part of our effort to understand the function and regulation of Elongin A in vivo, 
we have carried out the structure-function analysis of Elongin A and identified 
sequences critical for its nuclear localization and direct interaction with pol II. In 
addition, we have analyzed the rate of replication fork movement in wild-type and 
Elongin A-/- MEFs, and demonstrated the possibility that the genomic instability 
observed in Elongin A-/- MEFs might be caused by the replication fork collapse due to 
the lack of Elongin A. 
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Materials and methods 
 
Plasmid construction. DNA constructs expressing Elongin A mutants were generated 
by oligonucleotide-directed mutagenesis of pcDNA3.1-FLAG-Elongin A [16] using the 
QuickChange site-directed mutagenesis kit (Stratagene). For the expression of 
glutathione S-transferase (GST)-Elongin A fusion protein, cDNA encoding the entire rat 
Elongin A was amplified by PCR from pSVL-Elongin A [13], and subcloned into the 
BamHI and SalI sites of pGEX-4T1 (Amersham). Subsequently, constructs expressing 
GST fused to various Elongin A mutants were generated by oligonucleotide-directed 
mutagenesis using the QuickChange site-directed mutagenesis kit (Stratagene). 
Expression of recombinant proteins in Escherichia coli and in vitro binding assay. 
GST and GST-Elongin A fusion proteins were expressed in E. coli DH5α and purified 
using glutathione-sepharose affinity chromatography (Amersham) as described [16] 
according to the manufacturer's instructions. pol II was purified as described from rat 
liver nuclear extracts [17]. Immobilized GST fusion proteins (∼15 µg) were mixed with 
purified pol II and incubated for 1 h at 4°C. The beads were then washed five times with 
buffer containing 20 mM Hepes-NaOH (pH 7.9), 500 mM NaCl, 2.5 mM MgCl2, 50 
mM ZnCl2, 0.1 mM EDTA, 0.05% Nonidet P-40 and 0.5 mM DTT. Aliquots of loaded 
and bound fractions were subjected to SDS-polyacrylamide gel electrophoresis (PAGE), 
transferred to a polyvinylidene difluoride membrane (Millipore), and probed with anti- 
pol II (8WG16) antibody (Babco). Horseradish peroxidase-conjugated sheep anti-mouse 
antibody (Amersham) was used as a secondary antibody. Detection was performed 
using SuperSignal West Dura Extended Duration Substrate (Pierce). 
Immunofluorescence staining. Immunostaining of cells was performed as previously 
described [16, 18]. Briefly, COS7 cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and were 
transiently transfected with the pcDNA3.1/Hygro-FLAG-wild-type or mutant Elongin A 
using FuGENE 6 (Roche) according to the manufacturer’s protocol. The cells grown in 
a chamber slide were fixed by immersion in cold acetone/methanol (1:1) for 10 min, 
then rinsed with 70% ethanol, 50% ethanol and finally phosphate-buffered saline (PBS). 
After blocking in PBS containing 2% bovine serum albumin, 0.2% Tween 20 and 6.7% 
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glycerol at 4°C overnight, the cells were incubated for 1 h at 4 °C with rabbit polyclonal 
anti-FLAG antibody (1:1000) and mouse monoclonal anti-HA antibody. Reacting 
antibodies were stained with fluorescein-conjugated goat anti-rabbit IgG and 
rhodamine-conjugated goat anti-mouse IgG2b (Santa Cruz). Fluorescence microscopy of 
fixed cells was performed using an Olympus BX-50 confocal laser scanning 
microscope. 
Generation of Elongin A-deficient mice. Elongin A-deficient mice were generated as 
previously described [15]. Briefly, Elongin A mutant ES cell clones were microinjected 
into blastocysts for the generation of chimeric mice. Chimeric males were crossed with 
C57BL/6 females, and agouti-colored offspring were analyzed for the germline 
transmission of the Elongin A mutation. Heterozygous animals were intercrossed to 
generate homozygous mutant animals. 
PCR genotyping. Genomic DNA was isolated from embryonic yolk sacs, and 
genotyping was performed using PCR as described [15]. 
Preparation of MEFs. MEFs were prepared from E10.5 embryos as described [15]. 
Briefly, fetal tissue samples were rinsed in PBS and then were mechanically dissociated 
in DMEM with 10% FBS. The cells were then plated out on 6-well plates. These cells 
were considered to be passage 1 MEFs. 
Quantitative analysis of apoptosis in MEFs. For the quantitative analysis and to 
determine the cytoplasmic histone-associated DNA fragments, which are indicative of 
on-going apoptosis, the Cell Death Detection ELISAPLUS (Roche Applied Science) was 
used according to the manufacturer’s instructions. 
Replication labeling. Cells were labeled with biotin-16-dUTP and 
digoxigenin-11-dUTP (Roche Applied Science) at 20-min or 30-min intervals using 
hypotonic shift procedure with slight modifications [19]. Cells grown on a 
35-mm-diameter dish were washed with 1 ml of KH buffer (30 mM KCl, 10 mM 
HEPES, pH 7.4) and then 10 µl of KH buffer supplemented with 250 µM 
biotin-16-dUTP or digoxigenin-11-dUTP (Roche Applied Science) was added. After 
incubation at 37˚C with 5% CO2 for 10 min, the samples were washed with serum-free 
medium and cultured in normal medium for 20 min or 30 min to introduce modified 
nucleotides into nascent DNA. DNA fiber preparation was performed as described 
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previously [20, 21]. Replication labeled cells and 10- to 20-fold unlabeled cells were 
mixed before sample preparation because DNA fibers were extended straight and each 
replication-labeled DNA fiber was well separated. Cells were fixed with 
methanol/acetic acid (3:1) solution, dropped onto a slideglass, and then dipped into lysis 
buffer (0.5% SDS, 200 mM Tris-HCl, pH 7.4, 50 mM EDTA) for 10 min at 25˚C. DNA 
fibers were allowed to drop down from nuclei, dried and fixed with methanol/acetic 
acid (3:1) solution for 3 min at 25˚C. Biotin- and digoxigenin-labeled DNAs were 
detected using Alexa488-streptavidin (Invitrogen) and anti-digoxigenin conjugated with 
rhodamine (Roche Applied Science), respectively. 
Microarray analysis. Total RNA was isolated from Elongin A+/+ and Elongin A-/- 
MEFs according to the manufacturer’s protocol using an RNeasy Mini kit (Qiagen). 
One-microgram aliquots of total RNA were labeled using the Agilent Linear 
Amplification/Labeling kit (Agilent Technologies) according to the manufacturer’s 
instructions. After checking the labeling efficiency, 1-µg aliquots of Cy3-labeled 
Elongin A+/+ cRNA and Cy5-labeled Elongin A-/- cRNA were mixed, then hybridized to 
an Agilent Whole Mouse Oligo Microarray using the manufacturer’s hybridization 
protocol. After the washing step, the microarray slide was analyzed with an Agilent 
Microarray scanner and software (scanner model G2505B; software G2565BA). A data 
analysis was performed using the Agilent Feature Extraction software (Version 
A.6.1.1). 
 
Results and discussion 
 
Identification of the nuclear localization signals of Elongin A 
 
We have previously shown that Elongin A and its related family proteins are 
predominantly localized in the cell nucleus [16, 18]. In this study, we analyzed the 
sequences of Elongin A required for its nuclear localization using immunostaining 
assays. COS7 cells were transfected with constructs expressing wild-type or various 
deletion mutants of Elongin A with FLAG-tag at their NH2-terminus, and stained with 
anti-FLAG antibody. As shown in Fig. 1, the Elongin A mutant composed of residues 
400-589 was clearly localized in the nucleus. Analysis of the amino acid sequences in 
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this region of Elongin A indicated four short sequences rich in basic amino acids that 
resemble the potential nuclear localization signals (NLSs): amino acids 413 to 418 
(NLS1; RKKKKK), 433 to 435 (NLS2; KKK), 470 to 473 (NLS3; RPRK), and 509 to 
511 (NLS4; KRK) [22, 23]. In order to determine whether any of these sequences is 
functional, four additional deletion mutants that lacked either NLS1, NLS2, NLS3 or 
NLS4 from residues 400-589 of Elongin A were constructed. Transfection of COS7 
cells with expression vectors containing these deletion mutants demonstrated that 
NLS1, but not NLS2, NLS3 or NLS4, was required for nuclear localization, as the 
encoded protein missing NLS1 was identified in the cytoplasm (Fig. 1B). In contrast, 
the deletion of any of NLS2, NLS3 or NLS4 did not disrupt the nuclear localization of 
the encoded protein. 
 
Identification of Elongin A region responsible for the direct interaction with pol II 
 
In previous studies, we have demonstrated that Elongin A is capable of stimulating 
the rate of transcription elongation in vitro in the reaction mix containing only DNA 
template and pol II, and that the COOH terminus of Elongin A (residues 400-773) 
possesses a level of elongation stimulatory activity comparable to full-length Elongin A 
[8, 14]. From these findings, it was postulated that Elongin A interacts with pol II in a 
direct manner and that the amino acid sequences responsible for this interaction reside 
in residues 400-773 of Elongin A. 
Thus, to confirm the above presumptions, various truncation mutants of Elongin A 
were fused to GST, expressed in E. coli, and immobilized on glutathione-sepharose 
resin. These resins were then incubated with purified pol II. After extensive washing, 
the bound protein was eluted, fractionated on an SDS-PAGE gel, and probed with 
8WG16 antibody. As shown in Fig. 2, pol II was retained by the GST-Elongin 
A(400-773) affinity resins, while no detectable pol II was retained by the resin 
containing GST-Elongin A(1-399). Subsequent analysis demonstrated that GST fused 
with residues 590-690 of Elongin A bound to pol II. Meanwhile, GST fused with 
residues 1-120 of Elongin A, which is 29% identical and 53% similar to the 
NH2-terminus of SII and has been shown to interact with pol II holoenzyme complex 
[24], failed to bind to purified pol II.  
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Taken together, these results suggest: (i) residues 590-690 of Elongin A, which is the 
region highly conserved between Elongin A and its related family members, Elongins 
A2 and A3 [18], are responsible for the direct interaction with pol II; and (ii) interaction 
of the NH2 terminus of Elongin A with pol II seems to be indirect, and most likely 
mediated through some of the components of the pol II holoenzyme complex. 
 
Induction of genomic instability in Elongin A-/- MEFs 
 
To gain more insight into the role of Elongin A in vivo, we have recently generated 
Elongin A-deficient mice by gene targeting [15]. As shown in Fig. 3A, MEFs prepared 
from Elongin A-/- embryos indeed lack the endogenous Elongin A protein. As Elongin 
A-/- MEFs at E10.5 exhibited a slower growth rate compared with wild-type and 
Elongin A+/- MEFs, we have quantitatively analyzed the apoptotic status of E10.5 MEFs 
using cell death detection ELISA assays. Consistent with the findings obtained by 
annexin V-FITC and propidium iodide (PI) staining [15], Elongin A-/- MEFs showed a 
significant increase in histone-associated DNA fragmentation compared with the 
wild-type MEFs (Fig. 3B). Moreover, Elongin A-/- MEFs displayed the features of 
premature senescence, including a flattened and enlarged morphology and an elevated 
activity of senescence-associated β-galactosidase, accompanied by the activation of p53 
[15], suggesting that Elongin A-/- MEFs had sustained genomic instability due to the 
lack of Elongin A. 
Inhibition of the elongation phase of transcription by various agents, such as UV 
light, camptothecin or actinomycin D, has also been reported to lead to the activation of 
p53 and the induction of apoptosis [25, 26]. The induction of apoptosis following 
elongation blockage has been shown to occur preferentially in the S phase of the cell 
cycle [27]. As transcription also persists during the S phase of the cell cycle [28], it is 
possible that oncoming replication forks might occasionally collide with the blocked pol 
II elongation complexes, and that these collisions might lead to the stalling and 
breakdown of replication forks, resulting in genomic instability and the triggering of 
apoptosis. 
 
The rate of replication fork movement is significantly reduced in Elongin A-/- MEFs 
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Thus, as an initial step to examine this  possibility, we measured the rates of 
replication fork movement in non-synchronized wild-type and Elongin A-/- MEFs using 
the hypotonic shift method. The histograms in Fig. 4A represent the distribution of 
distances, where each replication fork has moved on DNA fibers during either 20 min 
(left panels) or 30 min (right panels). A fairly scattered pattern of distribution was 
observed. This is probably reflects the fact that the rate of replication fork movement is 
not constant during the S phase of the cell cycle [21]. Most notably, however, the 
proportion of the replication forks that had progressed only a short distance, i.e., less 
than 20 kb, within a given time was significantly larger in Elongin A-/- MEFs than in 
wild-type MEFs. The average rate of replication fork movement in Elongin A-/- MEFs 
was calculated to be approximately two-thirds of that in wild-type MEFs (Fig. 4B). 
These findings, therefore, support the possibility that the genomic instability observed 
in cells with transcriptional elongation impairment, including Elongin A-/- MEFs, could 
arise as a consequence of the replication fork collapse after collision with the blocked 
pol II (Fig. 4C). 
Next, to rule out the possibility that the observed reduction of the replication fork 
movement in Elongin A-/- MEFs is caused by the decreased expression of the factors 
involved in DNA replication at the transcriptional level by Elongin A deficiency, a 
cDNA microarray analysis comparing wild-type MEFs with Elongin A-/- MEFs was 
performed. Under our experimental conditions, mRNAs whose levels were decreased or 
increased by 2-fold or greater were considered to be differentially expressed transcripts. 
As shown in Table 1, the expression of the genes whose translational products play 
important roles in regulating the process of DNA replication was either not or was only 
weakly altered in Elongin A-/- MEFs, suggesting that the deficiency of replication 
factors might not be the cause of the replication fork impairment in Elongin A-/- MEFs. 
In addition, the expression levels of the pol II elongation factor-related genes, excluding 
Elongin A, did not significantly decrease. 
In summary, we have carried out the structure-function analysis of transcription 
elongation factor Elongin A and identified sequences critical for its functionthat is, i) 
nuclear localization, and ii) interaction with pol II. In addition, we have analyzed the 
rate of replication fork movement in wild-type and Elongin A-/- MEFs, and shown the 
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possibility that the genomic instability observed in Elongin A-/- MEFs might be caused 
by the replication fork collapse due to the lack of Elongin A. Therefore, it seems 
reasonable to speculate that Elongin A in cells plays roles not only in quantitatively 
regulating the synthesis of mRNA but also in maintaining the genomic stability by 
preventing pausing or arrest of the transcribing pol II. 
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Figure legends 
 
Fig. 1. Analysis of Elongin A region required for nuclear localization. (A) Structures of 
Elongin A mutants used in this study. On the right, the results of the assays shown in 
(B) are shown. (B) The subcellular localization of wild-type and mutant Elongin A. 
COS7 cells were transfected with FLAG-tagged wild-type or mutant Elongin A. After 
12 h, the cells were stained for wild-type or mutant Elongin A using anti-FLAG 
antibody (green). 
 
Fig. 2. Analysis of Elongin A region required for binding to pol II.  (A) Structures of 
Elongin A mutants used to produce chimeras with GST protein. On the right, the results 
of the assays shown in (B) are shown. (B) Purified pol II was incubated with GST (lanes 
2 and 10) or GST-Elongin A mutants (lanes 3-8 and 11-14). After extensive washing, 
the bound fractions were subjected to SDS-PAGE followed by Western blotting using 
8WG16 antibody. Ten percent of the total input of pol II was loaded in lanes 1 and 9. 
 
Fig. 3. Increased apoptosis in Elongin A-/- MEFs. (A) An expression analysis of 
endogenous Elongin A protein. Elongin A+/+, Elongin A+/-, and Elongin A-/- MEFs at 
passage 2 were analyzed by Western blotting using rabbit antiserum raised against the 
nonconserved amino-acid sequences (residues 758-772) located in the COOH-terminal 
portion of human Elongin A; α-tubulin was used as a loading control. (B) A 
quantitative analysis of apoptosis in Elongin A+/+ and Elongin A-/- MEFs. The level of 
apoptosis in MEFs was determined by ELISA quantification of cytoplasmic 
histone-associated DNA fragments. 
 
Fig. 4. Reduction of the rate of replication fork movement in Elongin A-/- MEFs. (A) 
Distribution of the distances that replication forks moved either in 20 min (left panels) 
or 30 min (right panels) in Elongin A+/+ (top) and Elongin A-/- (bottom) MEFs. (B) 
Rates of replication fork movement in Elongin A+/+ and Elongin A-/- MEFs. (C) A 
model to explain how the Elongin A deficiency causes genomic instability. The stalled 
pol II elongation complex may block the progression of replication fork movement. 
This would lead to a replication fork collapse, which could subsequently generate 
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recombinogenic DNA breaks or replication fork reversal. hnRNA, heterogeneous 
nuclear RNA. 
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Table 1  Changes in the expression of factors required for DNA replication 
and transcription elongation in wild-type and Elongin A-/- MEFs. 
 
A. DNA replication                                                                   Microarray 
 
Gene Name                                                                               Fold Change 
 
DNA polymerase α1, 180 kD subunit (Pola1)                                 +1.0 
DNA polymerase α2, 68 kD subunit (Pola2)                                   +1.0 
DNA polymerase β (Polb)                                                                -1.2 
DNA polymerase δ1, catalytic domain (Pold1)                                +1.1 
DNA polymerase ε (Pole)                                                                +1.4 
Proliferating cell nuclear antigen (Pcna)                                          +1.7 
Replication protein A, 30 kD subunit                                               +1.2 
Replication factor C1 (Recc1)                                                          -1.1 
Topoisomerase II α (Top2a)                                                            -1.5 
DNA ligase I, ATP dependent (Lig1)                                               +1.5 
Minichromosome maintenance deficient 7 (Mcm7)                         +1.7 
 
 
B. Transcription elongation                                                    Microarray 
 
Gene Name                                                                               Fold Change 
 
Elongin A (Tceb3)                                                                           -4.8 
SII (Tcea1)                                                                                      -1.7 
ELL (Ell)                                                                                         +1.1 
CA150 (Tcerg1)                                                                              -1.2 
pTEFb 
    Cyclin-dependent kinase 9 (Cdk9)                                             +1.0 
    Cyclin T1                                                                                     -1.1 
    Cyclin T2                                                                                     -1.3 
 
-Fold reductions (-) or increases (+) in Elongin A-/- MEFs of a subset of genes 
involved in DNA replication (A) or transcription elongation (B) are listed. 
Table 1
